Huang CS, Yang Y, Kwong A, Chen SC, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Res Treat 2021 Apr 15. pii: 10.1007/s10549-021-06166.
PMID: 33860389